Prime Medicine, Inc

Factor Bioscience Inc., located in Cambridge, MA, is devoted to advancing cell engineering to address diseases and elevate health standards. With over a decade of experience and a robust portfolio of more than 150 patents, the company focuses on developing transformative allogeneic cell therapies leveraging innovative technologies in mRNA gene editing, cell reprogramming, and nucleic acid delivery. The organization emphasizes collaboration with strategic partners throughout all stages of product development, from initial research to manufacturing support. Factor Bioscience aims to harness the potential of cell engineering in revolutionizing medicine for millions of patients, believing that their work can significantly impact the treatment and management of various health conditions, including cancer and rare diseases. Generated from the website

BGI Americas Corporation, based in Cambridge, MA, offers the Palisis platform, an all-in-one ticketing and reservation system designed to simplify operations for the travel industry. With seamless integrations to over 200 partners and a focus on streamlined business management, Palisis empowers companies to enhance their sales reach and improve customer experiences. Catering to various sectors, including sightseeing buses, tourist trains, and attractions, Palisis supports organizations by effectively managing ticket sales, reservations, and customer information in one unified solution. The platform's robust features enable businesses to tap into a wider market while reducing administrative burdens, allowing operators to focus on enhancing visitor engagement and maximizing profits. Generated from the website

Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.